, Volume 60, Issue 8, pp 1127-1135
Date: 09 Apr 2011

Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Although cancer immunology has made vigorous progress over the last decade, its future remains uncertain. Tumors have clearly proved subject to immune surveillance, leading to antigenic editing, and means of activating both T and B arms of the immune system have been devised. Therapeutic vaccination and monoclonal antibody therapy have so far proved disappointing, because tumors prove adept at evasion from immune control. Dual targeting could well counteract evasion, provided that the two targets are independent and are attacked simultaneously. This stage has nearly but not quite been reached in several forms of immunotherapy, particularly of B-cell cancers, although such treatment also carries hazards.

This paper is a Focussed Research Review based on a presentation given at the Tenth International Conference on Progress in Vaccination against Cancer (PIVAC 10), held in St. Catharine’s College, Cambridge, UK, 27–30th September 2010. It is part of a CII series of Focussed Research Reviews and meeting report.